Publication | Closed Access

Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Drug SafetyChemotherapy-induced NauseaPharmacologyOlanzapine 5NeuropharmacologyPharmacotherapyMedicineStandard Antiemetic TherapyAdverse Drug ReactionSide Effect